Literature DB >> 21900437

Prevalence, severity, and treatment of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue infections in 10 medical clinics in Texas: a South Texas Ambulatory Research Network (STARNet) study.

Nicolas A Forcade1, Michael L Parchman, James H Jorgensen, Liem C Du, Natalie R Nyren, Lucina B Treviño, Joel Peña, Michael W Mann, Abilio Muñoz, Sylvia B Treviño, Eric M Mortensen, Brian L Wickes, Brad H Pollock, Christopher R Frei.   

Abstract

OBJECTIVES: Quantify the prevalence, measure the severity, and describe treatment patterns in patients who present to medical clinics in Texas with community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft-tissue infections (SSTI).
METHODS: Ten primary care clinics participated in this prospective, community-based study. Clinicians consented patients and collected clinical information, pictures, and wound swabs; data were processed centrally. MRSASelect™ was used for identification. Susceptibilities were determined via Etest®.
RESULTS: Overall, 73 of 119 (61%) patients presenting with SSTIs meeting eligibility requirements had CA-MRSA. Among these, 49% were male, 79% were Hispanic, and 30% had diabetes. Half (56%) of the lesions were ≥ 5 cm in diameter. Most patients had abscesses (82%) and many reported pain scores of ≥ 7 of 10 (67%). Many presented with erythema (85%) or drainage (56%). Most received incision and drainage plus an antibiotic (64%). Antibiotic monotherapy was frequently prescribed: trimethoprim-sulfamethoxazole (TMP-SMX) (78%), clindamycin (4%), doxycycline (2%), and mupirocin (2%). The rest received TMP-SMX in combination with other antibiotics. TMP-SMX was frequently administered as one double-strength tablet twice daily. Isolates were 93% susceptible to clindamycin and 100% susceptible to TMP-SMX, doxycycline, vancomycin, and linezolid.
CONCLUSIONS: We report a predominance of CA-MRSA SSTIs, favorable antibiotic susceptibilities, and frequent use of TMP-SMX in primary care clinics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900437      PMCID: PMC3258020          DOI: 10.3122/jabfm.2011.05.110073

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  26 in total

1.  Practice guidelines for the diagnosis and management of skin and soft-tissue infections.

Authors:  Dennis L Stevens; Alan L Bisno; Henry F Chambers; E Dale Everett; Patchen Dellinger; Ellie J C Goldstein; Sherwood L Gorbach; Jan V Hirschmann; Edward L Kaplan; Jose G Montoya; James C Wade
Journal:  Clin Infect Dis       Date:  2005-10-14       Impact factor: 9.079

2.  Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome.

Authors:  Jörg J Ruhe; Nathaniel Smith; Robert W Bradsher; Anupama Menon
Journal:  Clin Infect Dis       Date:  2007-02-01       Impact factor: 9.079

3.  National epidemiology of cutaneous abscesses: 1996 to 2005.

Authors:  Breena R Taira; Adam J Singer; Henry C Thode; Christopher C Lee
Journal:  Am J Emerg Med       Date:  2009-03       Impact factor: 2.469

4.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

5.  Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned?

Authors:  James S Lewis; James H Jorgensen
Journal:  Clin Infect Dis       Date:  2004-12-21       Impact factor: 9.079

6.  Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  Jörg J Ruhe; Anupama Menon
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient.

Authors:  Myto Duong; Stephen Markwell; John Peter; Stephen Barenkamp
Journal:  Ann Emerg Med       Date:  2009-05-05       Impact factor: 5.721

8.  Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus.

Authors:  Michael C Lee; Ana M Rios; Monica Fonseca Aten; Asuncion Mejias; Dominick Cavuoti; George H McCracken; R Doug Hardy
Journal:  Pediatr Infect Dis J       Date:  2004-02       Impact factor: 2.129

9.  Risk factors for methicillin-resistant Staphylococcal aureus skin and soft tissue infections presenting in primary care: a South Texas Ambulatory Research Network (STARNet) study.

Authors:  Michael L Parchman; Abel Munoz
Journal:  J Am Board Fam Med       Date:  2009 Jul-Aug       Impact factor: 2.657

10.  Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection.

Authors:  Priya M Rajendran; David Young; Toby Maurer; Henry Chambers; Francoise Perdreau-Remington; Peter Ro; Hobart Harris
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

View more
  12 in total

Review 1.  Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure.

Authors:  Abraham Pulido-Cejudo; Mario Guzmán-Gutierrez; Abel Jalife-Montaño; Alejandro Ortiz-Covarrubias; Jose Luis Martínez-Ordaz; Héctor Faustino Noyola-Villalobos; Luis Mauricio Hurtado-López
Journal:  Ther Adv Infect Dis       Date:  2017-08-31

2.  Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment.

Authors:  Maciej Piotr Chlebicki; Choon Chiat Oh
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

3.  Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study.

Authors:  Matthew J Labreche; Grace C Lee; Russell T Attridge; Eric M Mortensen; Jim Koeller; Liem C Du; Natalie R Nyren; Lucina B Treviño; Sylvia B Treviño; Joel Peña; Michael W Mann; Abilio Muñoz; Yolanda Marcos; Guillermo Rocha; Stella Koretsky; Sandra Esparza; Mitchell Finnie; Steven D Dallas; Michael L Parchman; Christopher R Frei
Journal:  J Am Board Fam Med       Date:  2013 Sep-Oct       Impact factor: 2.657

4.  Socio-economic profile of patients with community-acquired skin and soft tissue infections in Delhi.

Authors:  Arjun Ravishankar; Seema Singh; Sumit Rai; Naveen Sharma; Sanjay Gupta; Rajat Thawani
Journal:  Pathog Glob Health       Date:  2014-10-07       Impact factor: 2.894

5.  Worsening Glycemia Increases the Odds of Intermittent but Not Persistent Staphylococcus aureus Nasal Carriage in Two Cohorts of Mexican American Adults.

Authors:  Heather T Essigmann; Craig L Hanis; Stacia M DeSantis; William B Perkison; David A Aguilar; Goo Jun; D Ashley Robinson; Eric L Brown
Journal:  Microbiol Spectr       Date:  2022-05-18

6.  Emerging multidrug resistance in community-associated Staphylococcus aureus involved in skin and soft tissue infections and nasal colonization.

Authors:  Grace C Lee; Steven D Dallas; Yufeng Wang; Randall J Olsen; Kenneth A Lawson; James Wilson; Christopher R Frei
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790

7.  Antimicrobial resistance profile of Staphylococcus aureus isolates obtained from skin and soft tissue infections of outpatients from a university hospital in Recife -PE, Brazil.

Authors:  Fabiana Beserra Caraciolo; Maria Amélia Vieira Maciel; Josemir Belo dos Santos; Marcelle Aquino Rabelo; Vera Magalhães
Journal:  An Bras Dermatol       Date:  2012 Nov-Dec       Impact factor: 1.896

8.  Predictors of community-associated Staphylococcus aureus, methicillin-resistant and methicillin-susceptible Staphylococcus aureus skin and soft tissue infections in primary-care settings.

Authors:  G C Lee; R G Hall; N K Boyd; S D Dallas; L C Du; L B Treviño; C Retzloff; S B Treviño; K A Lawson; J P Wilson; R J Olsen; Y Wang; C R Frei
Journal:  Epidemiol Infect       Date:  2016-08-04       Impact factor: 4.434

9.  Targeting RNA polymerase primary σ70 as a therapeutic strategy against methicillin-resistant Staphylococcus aureus by antisense peptide nucleic acid.

Authors:  Hui Bai; Guojun Sang; Yu You; Xiaoyan Xue; Ying Zhou; Zheng Hou; Jingru Meng; Xiaoxing Luo
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

10.  Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections.

Authors:  Shankar Thangamani; Waleed Younis; Mohamed N Seleem
Journal:  Sci Rep       Date:  2015-06-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.